S&P 500 Healthcare Sector SEC Filings — April 01, 2026

01-04-2026

Lakewood-Amedex Biotherapeutics Inc. (LABT) filed Amendment No. 4 to its Form S-1 registration statement on April 1, 2026, for a direct listing on the Nasdaq Capital Market under the symbol LABT, registering 4,689,177 shares of common stock for resale by existing stockholders, from which the company will receive no proceeds. The company engaged RBW Capital Partners LLC as financial advisor (to receive 272,219 unregistered shares equal to 1.75% of fully diluted shares outstanding) and placement agent (7% fee) for a concurrent private placement of 937,500 shares of Series C Preferred Stock at $10.00 per share, raising $7,500,000 gross proceeds prior to listing. The direct listing process is novel and may result in volatile trading, with Nasdaq approval required and no assurance of listing success.

• ·Series C Preferred Stock stated value $10.00 per share, convertible into common stock at lower of $10.00 or 80% of 5-day average closing price (floor $1.00).
• ·Company classified as emerging growth company and smaller reporting company, electing reduced reporting requirements.
• ·Resale registration statement for Series C underlying common stock and advisory shares to be filed within 10 days of Nasdaq listing.
• ·Listing contingent on Nasdaq approval; if not approved, direct listing will be terminated.

01-04-2026

Loews Corporation filed a DEFA14A (Definitive Additional Proxy Materials) on April 01, 2026, pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and is marked as Definitive Additional Materials. No specific financial data, proposals, or other substantive details are provided in the available content.

01-04-2026

Commercial Vehicle Group (CVGI) announced that Chief Financial Officer Andy Cheung will resign effective April 15, 2026, to become CFO of a mid-cap publicly traded company. Angie O’Leary, current Corporate Controller and Chief Accounting Officer, has been promoted to Interim CFO while retaining her existing roles. The company reaffirmed its full-year 2026 outlook from its Q4 2025 earnings release on March 10, 2026, and stated it does not intend to initiate a search for a permanent CFO replacement at this time.

• ·Angie O’Leary joined CVG as Senior Vice President, Corporate Controller and Chief Accounting Officer in December 2020; previously held roles at Vertiv Holdings Co. from May 2017 to December 2020, including Interim Corporate Controller, and at Deloitte & Touche LLP from January 2004 to May 2017, culminating as Senior Manager – Audit.
• ·Angie O’Leary holds a Bachelor of Science in Business Administration and Master of Accounting from The Ohio State University (2003) and is a Certified Public Accountant since 2005.
• ·Investor contacts: Michelle.Hards@cvgrp.com; Ross Collins or Nathan Skown at Alpha IR Group (15004906036.2).

01-04-2026

Coca-Cola Europacific Partners plc (CCEP) announced the appointment of Svetlana Walker as General Counsel and Company Secretary effective April 1, 2026, succeeding Clare Wardle who has stepped down after significant contributions. Svetlana Walker brings over 20 years of international legal and compliance experience, most recently as General Counsel and Chief Compliance Officer at Klöckner Pentaplast Group. CCEP serves nearly 600 million consumers and over 4 million customers across 31 countries.

• ·CCEP listed on Euronext Amsterdam, NASDAQ (NASDAQ 100 constituent), London Stock Exchange, and Spanish Stock Exchanges under symbol CCEP (ISIN GB00BDCPN049).

01-04-2026

Artificial Intelligence Technology Solutions, Inc. (AITX) filed an 8-K on April 1, 2026, under Item 8.01 announcing the issuance of a press release titled 'AITX's RAD Retained Through Property Sale as New Owner Validates Autonomous Security Performance.' The press release, attached as Exhibit 99.1, highlights the retention of AITX's RAD system by a property's new owner post-sale, validating its autonomous security capabilities. No financial metrics or period comparisons were disclosed.

• ·Filing is furnished under Item 8.01 and not deemed 'filed' for liability purposes.
• ·Registrant details: Nevada incorporation, CIK 0001498148, EIN 27-2343603, principal office at 10800 Galaxie Avenue, Ferndale, Michigan 48220.

01-04-2026

News Corporation disclosed in an 8-K filing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program for Class A (NWSA) and Class B (NWS) common stock. The program authorizes repurchases of up to $1 billion in aggregate, with daily transaction disclosures to ASX if any occur, and periodic updates in quarterly/annual reports. Exhibits 99.1 and 99.2 contain the specific ASX disclosures on their respective dates, including forward-looking statements about repurchase intentions.

• ·Date of earliest event reported: March 31, 2026
• ·Filing date: April 01, 2026
• ·Registrant details: Delaware incorporation, Commission File Number 001-35769, IRS EIN 46-2950970

01-04-2026

NewHold Investment Corp III, a SPAC, completed its IPO in 2025, raising funds that resulted in $209,220,000 held in the Trust Account from 20,125,000 Class A ordinary shares subject to redemption at $10.40 per share, and reported net income of $4,918,000 for the year ended December 31, 2025, driven by $7,008,000 in interest and other income offsetting $2,090,000 in G&A expenses. However, the company incurred an operating loss of $2,090,000, shareholders' deficit widened to $6,961,000 from $65,000 at year-end 2024 due to accretion and transaction costs, and remains pre-business combination with ongoing risks to complete an acquisition.

• ·Class A ordinary shares basic and diluted net income per share: $0.20 for year ended Dec 31, 2025
• ·Class B ordinary shares basic and diluted net income per share: $0.20 for year ended Dec 31, 2025; $(0.01) for prior period
• ·Weighted average Class A ordinary shares outstanding: 17,354,000 for year ended Dec 31, 2025
• ·Private Placement Units: 780,100 issued at $10.00 per unit
• ·Promissory note – related party: $240,000 outstanding as of Dec 31, 2024 (paid off by 2025)

01-04-2026

B. Riley Financial, Inc. reported FY 2025 total revenues of $967,599 up 29.6% YoY from $746,421, primarily due to trading gains swinging to $125,530 from a $57,007 loss, and a net income turnaround to $307,415 attributable to BRC Group Holdings, Inc. from a $764,274 loss. However, core services and fees revenues declined 19.1% to $633,836 across all major segments including Capital Markets (-17.3%), Wealth Management (-20.0%), and Lingo (-16.2%), while operating cash flow shifted to negative $(59,711) from $263,551 provided.

• ·Senior notes payable reduced to $1,301,798 from $1,530,561 YoY.
• ·Total equity securities increased to $368,804 from $232,508.
• ·Discontinued operations income declined to $70,841 from $147,470.
• ·Net cash decrease of $27,399 vs increase of $22,837 prior year.

01-04-2026

Zymeworks Inc. (Nasdaq: ZYME) announced the appointment of Kristin Stafford as Chief Financial Officer, effective April 1, 2026, to support strategic planning, capital allocation, and value creation. Stafford brings extensive experience from Royalty Pharma plc, BioPharma Credit plc, Ernst & Young LLP, and Deloitte. No financial metrics or performance changes were disclosed in the announcement.

• ·Stafford served as Senior Vice President, Chief Accounting Officer at Royalty Pharma since December 2018; previously Vice President, Finance at Royalty Pharma and CFO of BioPharma Credit plc (2016-2018).
• ·Stafford is a CPA, holds B.Sc. in business administration from Sonoma State University, and is currently a Board Member at Novocure.
• ·Filing includes standard forward-looking statement risks, such as clinical trial failures, regulatory delays, and partnership challenges.

01-04-2026

Circle Internet Group, Inc. (CRCL) filed Definitive Additional Proxy Materials (DEFA14A) for its 2026 Annual Meeting scheduled for May 14, 2026, at 10:00 a.m. ET virtually. Shareholders are to vote on electing three Class I directors (Jeremy Allaire, Craig Broderick, P. Sean Neville), an advisory vote to approve named executive officer compensation, advisory vote on the frequency of future compensation votes (board recommends 1 Year), and ratification of Deloitte & Touche LLP as independent auditors, with the board recommending FOR all items.

• ·Vote by May 13, 2026, 11:59 PM ET at www.ProxyVote.com
• ·Request proxy materials by April 30, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting at www.virtualshareholdermeeting.com/CRCL2026

01-04-2026

Green Thumb Industries Inc. amended its Trademark and Recipe License Agreements with RYTHM, Inc. subsidiaries effective April 1, 2026, transitioning licensing fees from revenue-based to fixed annual cash payments of $70 million collectively for brands including RYTHM Premium Cannabis, incredibles, Beboe, Dogwalkers, Doctor Solomon's, &Shine, and Good Green. Fees are payable monthly and subject to annual increases based on two times a CPI escalator, with no other terms changed. As a significant shareholder in RYTHM, Green Thumb is positioned to benefit from its growth.

01-04-2026

Scinai Immunotherapeutics Ltd. reports a history of operating losses and lack of current profitability, despite generating revenues from its CDMO activities, with risks of continued losses due to market demand dependencies and partner performance issues. The company highlights competitive strengths in its dual business model combining R&D drug development with CDMO operations, which provides financial flexibility, generates external revenues, and supports internal programs to reduce cash burn. However, regulatory risks including state anti-kickback laws and partner failures could delay pipeline commercialization and impact revenues.

01-04-2026

Donnelley Financial Solutions, Inc. (DFIN) issued definitive additional proxy materials (DEFA14A) for its Annual Meeting of Stockholders on May 14, 2025, at 1:30 PM Central Time, held virtually via www.proxydocs.com/DFIN. Key proposals include electing director nominees for a one-year term, an advisory vote on executive compensation, amending the Amended and Restated 2016 Performance Incentive Plan, and ratifying Deloitte & Touche LLP as the independent registered public accounting firm. The Board of Directors recommends a FOR vote on Proposals 1, 2, 3, and 4.

• ·Record date for stockholders: March 17, 2025
• ·Meeting requires pre-registration at www.proxydocs.com/DFIN
• ·Proxy materials available online at www.proxydocs.com/DFIN; paper requests via www.investorelections.com/DFIN
• ·Filing date: April 01, 2026

01-04-2026

UBS Commercial Mortgage Trust 2019-C16 announced that Mount Street US (Georgia) LLP was removed as special servicer for the Colonnade Office Complex Mortgage Loan, which constituted approximately 6.9% of the asset pool as of the cut-off date, and CWCapital Asset Management LLC was appointed as successor special servicer effective April 1, 2026, pursuant to Section 7.01(d) of the UBS 2019-C16 PSA. This change is in the interest of transaction management. No financial performance metrics, improvements, declines, or other impacts were disclosed.

• ·Pooling and Servicing Agreement (PSA) dated April 1, 2019, filed as Exhibit 4.1 to Form 8-K on April 16, 2019.
• ·CWCAM servicing office: 900 19th Street NW, 8th Floor, Washington, D.C. 20006.

01-04-2026

Wells Fargo Commercial Mortgage Trust 2019-C50 filed an 8-K announcing that the Colonnade Office Complex Mortgage Loan, constituting approximately 3.0% of the asset pool as of its cut-off date, will now be specially serviced by CWCapital Asset Management LLC (CWCAM) as successor special servicer, effective April 1, 2026. Mount Street US (Georgia) LLP was removed from this role pursuant to Section 7.01(d) of the UBS 2019-C16 PSA. This change is for transaction management purposes with no reported impact on performance metrics.

• ·Change effective as of April 1, 2026, pursuant to Section 7.01(d) of the UBS 2019-C16 PSA dated April 1, 2019.
• ·CWCAM servicing office: 900 19th Street NW, 8th Floor, Washington, D.C. 20006.
• ·Loan is part of a loan combination serviced and administered under the UBS 2019-C16 PSA.

01-04-2026

Comenity Bank and Comenity Servicing LLC executed the Sixth Addendum to the Sixth Amended and Restated Service Agreement, effective April 1, 2026, amending Services in Appendix A (including Digital Engineering for Omnichannel Platform, Mobile App, Loyalty and Rewards; Servicing and Core Processing Engineering for VCARS, IVR, Jack Henry, Fiserv platforms, Servicing AI Assistant) and Performance Standards in Appendix B. Amendments reorganize standards such as adding and deleting 99.9% availability targets for PLP Services Rewards Website Fulfillment on a monthly basis. The Agreement, originally dated January 1, 2025, continues in full force and effect except as modified.

• ·Original Sixth Amended and Restated Service Agreement dated January 1, 2025
• ·Amendments detailed in Exhibit A (Services) and Exhibit B (Performance Standards)

01-04-2026

Fulton Financial Corporation filed its definitive proxy statement (DEF 14A) on April 1, 2026, for the 2026 Annual Meeting of Shareholders on May 28, 2026, seeking shareholder approval for the election of ten director nominees for one-year terms, a non-binding advisory vote on named executive officers' compensation, and ratification of KPMG LLP as independent auditor for the fiscal year ending December 31, 2026. The record date for shareholders entitled to vote is March 2, 2026. The proxy accompanies the 2025 Annual Report on Form 10-K and includes references to executive compensation data for principal executive officers (e.g., Mr. Myers) and non-PEO NEOs across 2021-2025, though specific figures are not detailed in the filing excerpt.

• ·Annual Meeting location: Lancaster Marriott at Penn Square, 25 South Queen Street, Lancaster, Pennsylvania 17603
• ·Fiscal year end: December 31
• ·Proxy materials mailing expected on or about April 1, 2026
• ·Compensation disclosures cover periods 2021-2025, including stock/option awards, fair value changes, vested awards, and dividends for PEO and non-PEO NEOs

01-04-2026

On March 31, 2026, Greg Campbell resigned from the Board of Directors of Newton Golf Company, Inc. (NWTG), effective immediately, with no disagreement on the company's operations, policies, or practices. The filing was signed by Akinobu Yorihiro, Interim Chief Executive Officer and Chief Technology Officer. No other changes or compensatory arrangements were disclosed.

• ·Company is an emerging growth company.
• ·Common stock trades as NWTG on Nasdaq Stock Market LLC, par value $0.01 per share.
• ·Principal executive offices: 551 Calle San Pablo, Camarillo, CA 93012.

01-04-2026

Ares Commercial Real Estate Corporation (ACRE) filed a DEFA14A proxy statement for its 2026 Annual Meeting of Stockholders, scheduled virtually on May 27, 2026 at 1:00 PM ET. Key proposals include the election of William S. Benjamin and Caroline E. Blakely as Class II Directors until the 2029 Annual Meeting, ratification of Ernst & Young LLP as independent auditors for the fiscal year ending December 31, 2026, and an advisory vote to approve named executive officers' compensation for the fiscal year ended December 31, 2025. No financial performance metrics or period-over-period comparisons are detailed in this filing.

• ·Vote by May 26, 2026 11:59 PM ET via www.ProxyVote.com
• ·Request proxy materials by May 13, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting access: www.virtualshareholdermeeting.com/ACRE2026
• ·Address: 245 Park Avenue, 42nd Floor, New York, NY 10167

01-04-2026

Interpace Biosciences reported Q4 2025 revenue of $9.2 million, down 26% YoY on GAAP basis due to PancraGEN discontinuation but up 20% vs pro forma prior quarter; full-year revenue was $38.7 million, down 18% YoY GAAP but up 17% pro forma. Thyroid revenue and volume showed strong growth with Q4 increases of 14% and 11% YoY, and FY gains of 21% and 13% YoY, respectively; however, Adjusted EBITDA declined to $1.7 million in Q4 (vs $2.2 million prior) and $5.4 million FY (vs $8.7 million prior), and income from continuing operations benefited from a one-time non-cash tax adjustment.

• ·Debt fully paid off in Q4 2025.
• ·Cash availability increased $4.3 million year-over-year.
• ·Q4 cash collections $9.6M vs $11.2M prior year GAAP and $10.1M pro forma.
• ·FY cash collections $41.7M vs $43.6M prior year GAAP.
• ·Guidance for approximately 16% YoY thyroid revenue growth in 2026.

01-04-2026

Nexscient, Inc. (NXNT) completed the acquisition of Flipside AI for $6.20 million, consisting of $600,000 cash, $450,000 convertible note, and 6,846,000 shares of restricted common stock, enhancing its Physical AI data engineering capabilities. Anthony S. De Luna, Flipside AI's founder and CEO, was appointed as Nexscient's Chief Technology Officer and Board Director. The deal positions Nexscient to capitalize on the AI robotics market projected to grow from $16.1 billion in 2024 to $124.8 billion by 2030.

• ·Acquisition includes satisfaction of all customary closing conditions, multi-step reorganization, regulatory filings, and government clearances.
• ·Flipside AI founded in 2010, pivoted to AI data engineering in 2018; serves automotive OEMs, Tier-1 suppliers, autonomous vehicle programs, robotics developers, and satellite intelligence platforms.
• ·Anthony S. De Luna has over three decades of experience, including XML at Innodata Inc. (1990s), EPUB at Barnes & Noble (2000s), and Physical AI from 2018.

01-04-2026

Alerus Financial Corporation (ALRS) has issued its DEF 14A proxy statement for the virtual annual stockholder meeting on May 14, 2026, at 1:30 p.m. Central Time, with a record date of March 16, 2026. Key proposals include the election of directors, a non-binding advisory vote on executive officer compensation, and ratification of RSM US LLP as the independent registered public accounting firm. The statement references the Annual Report on Form 10-K for the year ended December 31, 2025, and provides access details for proxy materials online.

• ·Virtual meeting access: https://edge.media-server.com/mmc/p/52pjzmgx with passcode 'alerus2026' and 11-digit control number.
• ·Proxy materials available at investors.alerus.com and http://www.astproxyportal.com/ast/19579/.
• ·Notice first mailed on or about April 1, 2026.

01-04-2026

abrdn National Municipal Income Fund (NYSE: VFL) adjourned its Special Shareholder Meeting on April 1, 2026, to April 15, 2026, at 11:00 am Eastern Time, to solicit additional proxies and achieve quorum. The meeting concerns approval of an Agreement and Plan of Reorganization with MFS Municipal Income Trust (NYSE: MFM), which the Board of Trustees unanimously recommends. Aberdeen Investments, the manager, had approximately $525 billion in assets under management as of December 31, 2025.

• ·Proxy materials available on www.sec.gov and via mail.
• ·Contact: Aberdeen Investments U.S. Closed-End Funds Investor Relations at 1-800-522-5465 or investor.relations@aberdeenplc.com

01-04-2026

O’Reilly Automotive, Inc. filed an 8-K on April 1, 2026, under Items 7.01 (Regulation FD Disclosure) and 9.01, announcing via press release (Exhibit 99.1) the dates of its first quarter 2026 earnings release and conference call. This disclosure ensures timely public dissemination of material information. No financial results or other metrics were provided.

01-04-2026

Cinemark Holdings, Inc. (CNK) filed a DEFA14A notice regarding the availability of proxy materials for its Annual Stockholders Meeting on May 14, 2026, for stockholders of record as of March 19, 2026. Proposals include the election of four Class I directors (Nancy Loewe, Steven Rosenberg, Enrique Senior, Nina Vaca) for terms expiring in 2029, an advisory vote to approve named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditors. The Board of Directors recommends voting FOR all three proposals.

• ·Paper materials can be ordered via www.investorelections.com/CNK, call 1-866-648-8133, or email paper@investorelections.com using the 12-digit control number.
• ·No other requests or inquiries should be included in email subject line beyond the control number.

01-04-2026

MVB Financial Corp. and its subsidiary MVB Bank, Inc. announced via press release that Michael L. Giorgio's role has been expanded to include Chief Operating Officer alongside his existing Chief Information Officer position, effective April 1, 2026. The disclosure was made under Regulation FD to ensure fair public dissemination of the information.

• ·Press release filed as Exhibit 99.1
• ·SEC filing under Items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits)

01-04-2026

Senti Biosciences, Inc. announced on April 1, 2026, plans for a holding company reorganization effective by April 16, 2026, via a tax-free merger of the Company into Senti Biosciences Merger Sub, Inc., a subsidiary of Senti Biosciences Holdings, Inc. Company common stock will automatically convert one-for-one into Holdings common stock with identical rights, continuing to trade under 'SNTI' on Nasdaq Capital Market with a new CUSIP. The reorganization requires no stockholder vote, preserves directors, officers, assets, and operations, but may be delayed or not implemented.

• ·Reorganization pursuant to Section 251(g) of Delaware General Corporation Law.
• ·Tax-free for U.S. federal income tax purposes.
• ·Stock certificates and book-entries continue to represent equivalent Holdings shares post-reorganization.

01-04-2026

Alto Neuroscience, Inc. (ANRO) filed an 8-K on April 1, 2026, announcing the issuance of a press release detailing topline data from its Phase 2 proof-of-concept study of ALTO-101 and highlighting pipeline advancements. The full press release is incorporated as Exhibit 99.1. No quantitative financial or clinical results are provided in the filing itself.

• ·Filing includes Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits).
• ·Common Stock trades on NYSE under symbol ANRO.

01-04-2026

iSpecimen Inc. reported shifts in revenue mix for 2025 versus 2024, with remnant biofluids increasing to 23% from 11%, research use only biofluids rising to 56% from 49%, and hematopoietic stem and immune cells growing to 3% from 1%; however, research use only tissue declined sharply to 18% from 39%. Customer concentration eased to one customer at 20% of 2025 revenue from 29% in 2024. The company faces ongoing losses from uncollected sales tax obligations in prior years, with revenue described as transactional and non-recurring.

• ·Revenue is transactional and not recurring; no charges for access to iSpecimen Marketplace.
• ·Company incurred losses from sales tax obligations due to not collecting taxes on prior taxable sales, with uncertain recovery from customers.
• ·Filing date: April 01, 2026

01-04-2026

South Plains Financial, Inc. (NASDAQ:SPFI), parent of City Bank, completed the merger of BOH Holdings, Inc. into itself and BOH's subsidiary Bank of Houston into City Bank, effective April 1, 2026. As of December 31, 2025, BOH had total assets of $744 million, total loans of $624 million, and total deposits of $603 million. Financial advisors were Raymond James & Associates, Inc. and Hillworth Bank Partners, with legal advisors Hunton Andrews Kurth LLP for South Plains and Fenimore Kay Harrison LLP for BOH.

• ·Filing items: 2.01, 5.02, 8.01, 9.01
• ·Contact: (866) 771-3347, investors@city.bank

01-04-2026

Klotho Neurosciences, Inc. reported total assets of $9,593,240 as of December 31, 2025, up significantly from $2,457,365 in 2024, with cash and cash equivalents surging to $7,176,615 from $63,741, supported by $13,002,128 in net cash from financing activities and working capital turning positive at $7,216,922 from a deficit of $1,089,723. However, the net loss widened to $10,551,674 from $6,150,372, driven by a 29% increase in operating expenses to $7,146,265, including new research and development costs of $634,187 and higher professional fees. Shares outstanding grew to 72,536,722 from 27,080,915 amid multiple issuances and conversions.

• ·Warrant liability increased to $53,000 from $24,486.
• ·Research and development expenses initiated at $634,187 in 2025 (none in 2024).
• ·Share-based compensation decreased to $1,565,212 from $2,649,573.
• ·Total liabilities decreased to $129,764 from $1,272,020.
• ·Accumulated deficit grew to $21,114,473 from $10,562,799.

01-04-2026

Associated Banc-Corp completed its merger with American National Corporation and its bank subsidiary, American National Bank, enhancing organic growth potential in markets like Omaha and the Twin Cities. The acquisition builds on Associated's strong 2025 performance, including relationship loan and deposit growth, record customer growth, solid credit performance, and the strongest annual net income in company history. Wende Kotouc, former Executive Co-Chairperson and Co-CEO of American National Bank, was appointed to Associated's Board of Directors.

• ·American National systems, branches, and customers expected to convert to Associated in Q3 2026.
• ·Associated operates over 200 banking locations in Wisconsin, Illinois, Iowa, Minnesota, Missouri, and Nebraska, with loan production offices in Indiana, Kansas, Michigan, New York, Ohio, and Texas.

01-04-2026

CVB Financial Corp announced that all requisite regulatory approvals have been received for its previously announced all-stock merger with Heritage Commerce Corp, including a Federal Reserve Section 3 waiver and non-objection letter on March 30, 2026, and Office of the Comptroller of the Currency approval on April 1, 2026. Under the Merger Agreement dated December 17, 2025, Heritage Commerce Corp will merge into CVBF, and its banking subsidiary, Heritage Bank of Commerce, will merge into CVBF's Citizens Business Bank. The transaction is expected to close on April 17, 2026, subject to customary closing conditions.

• ·Press release dated April 1, 2026, attached as Exhibit 99.1.
• ·CVBF Form S-4 filed February 10, 2026, declared effective February 12, 2026.

01-04-2026

SCI Engineered Materials, Inc. (SCIA) announced the retirement of Gerald S. Blaskie, its Chief Financial Officer, Treasurer, and Assistant Secretary, effective April 1, 2026, following a 25-year career with the company previously announced on September 29, 2025. During his tenure since joining in April 2001, revenue grew significantly, SCI achieved consistent profitability for the past eight years, repaid all outstanding debt in 2024, and maintained a strong balance sheet with $7.9 million in cash and cash equivalents plus approximately $3.4 million in marketable securities as of December 31, 2025. The company remains debt-free and is investing in new manufacturing equipment for continued growth.

• ·Mr. Blaskie was elected Vice President, Treasurer and Assistant Secretary in March 2006.
• ·Prior roles: Controller at Cable Link, Inc. (Feb 2000-Mar 2001); Plant Manager (1997-2000) and Controller (1993-1997) at Central Ohio Plastics Corporation.
• ·Mr. Blaskie earned a B.S. in Accounting from Central Michigan University and passed the CPA exam in Ohio.

01-04-2026

Jupiter Neurosciences, Inc. (JUNS) discloses substantial risks in its 10-K filing, including no meaningful revenue from product sales to date, significant net losses since inception with expectations of continued losses, and management's conclusion of substantial doubt about going concern for fiscal years ended December 31, 2025 and 2024, corroborated by the auditor's explanatory paragraph. The company faces challenges from substantial indebtedness tied to convertible promissory notes under the Standby Equity Purchase Agreement, low common stock trading volume limiting draws, dependence on the exclusive worldwide license with Aquanova for Nugevia and pharmaceutical products, and risks in developing JOTROL™ amid competition and capital needs. Recent sales of unregistered securities include grants of 78,186 and 25,000 common shares to service providers on April 23, 2025, at $0.64 per share.

• ·Auditor included explanatory paragraph on going concern in audit reports for fiscal years ended December 31, 2025 and 2024.
• ·Non-refundable fees under Strategic Service Agreement with DOMINANT TREASURE HEALTH COMPANY LIMITED not tied to milestones or performance.
• ·Shares issued in advance to Asian Partners for specific services in Southeast Asia, with potential material negative impact if services not performed.

01-04-2026

New Fortress Energy Inc. (NFE) announced over 95% support from lenders for its Restructuring Support Agreement (RSA) covering approximately $5.8 billion in aggregate indebtedness, with support levels at 93% for 2026 Legacy Notes, 87% for 2029 Legacy Notes, 98% for 2029 New Notes, 100% for Term Loan A, 88% for Term Loan B, and 100% for Revolving Credit Facility. The company extended the early consent deadline to April 8, 2026, at 5:00pm NYC time to allow more time for accession. The UK Restructuring Plan is on track to launch in April 2026 and complete by Q3 2026.

• ·RSA entered into on March 17, 2026
• ·Contact for accession: nfe@is.kroll.com; website https://deals.is.kroll.com/nfe
• ·References prior SEC filings: 10-K for FY ended Dec 31, 2024 (filed Mar 10, 2025); DEF 14A filed Apr 29, 2025; 10-Q for Q3 2025

01-04-2026

Forte Biosciences reported full-year 2025 financial results, with research and development expenses surging to $58.2 million from $21.2 million in 2024 due to increased manufacturing, clinical trials, and personnel costs for FB102 programs in celiac disease, vitiligo, and alopecia areata, while general and administrative expenses decreased to $12.4 million from $15.4 million. This led to a widened net loss of $69.4 million ($4.71 per share) from $35.5 million ($12.17 per share), though cash and cash equivalents strengthened to $77.0 million from $22.2 million, providing runway for anticipated 2026 clinical readouts. CEO Paul Wagner highlighted FB102's progress and multi-billion dollar market potential across autoimmune indications.

• ·Accounts payable increased to $9.99 million from $4.88 million as of Dec 31, 2025.
• ·Accrued liabilities increased to $10.76 million from $4.20 million as of Dec 31, 2025.
• ·Accumulated deficit grew to $(223.4 million) from $(154.0 million) as of Dec 31, 2025.
• ·Weighted average shares and pre-funded warrants outstanding: 14,717,734 in 2025 vs 2,915,894 in 2024.

01-04-2026

TuHURA Biosciences reported FY 2025 financial results with cash of $3.6 million at year-end (plus $7.5 million received in Q1 2026), R&D expenses up 54% YoY to $20.5 million, G&A up 95% to $7.6 million, and operating cash burn increasing 88% to $27.7 million, offset by $21.2 million raised via offerings and $19.9 million in net financing inflows (down from $29.7 million prior year). Corporate highlights include initiating Phase 3 trial for IFx-2.0 in MCC under FDA SPA, Phase 1b/2a in MCCUP, and closing $10.5 million acquisition of Kineta for TBS-2025 rights, with multiple milestones targeted for 2026-2027. While pipeline advances continue, elevated expenses and low cash position highlight ongoing funding needs.

• ·Phase 3 IFx-2.0 enrollment now anticipated to complete mid-2027.
• ·FDA meeting for TBS-2025 in NPM1 mut r/r AML planned for June 2026.
• ·Merger with Kineta closed on June 30, 2025.

01-04-2026

ONEOK, Inc. filed its definitive 2026 Proxy Statement on April 1, 2026, for the virtual annual shareholder meeting on May 20, 2026, at 9:00 a.m. CDT. Shareholders will vote on electing ten director nominees, ratifying PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, and an advisory approval of executive compensation. The record date for voting eligibility is March 23, 2026.

• ·Virtual meeting registration at www.proxydocs.com/oke
• ·Proxy materials available at www.oneok.com and www.proxydocs.com/oke

01-04-2026

Lifeway Foods, Inc. provided preliminary financial outlook for Q1 ended March 31, 2026, projecting net sales of $60.8 million to $62.3 million, a 32% to 35% increase over Q1 2025, driven by strong demand for kefir and farmer cheese. The company highlighted continued momentum in its core probiotic portfolio with no reported declines or flat segments. Full Q1 2026 results will be reported on May 14, 2026, ahead of a 9am ET conference call.

• ·Earnings conference call and webcast at 9am ET on May 14, 2026, available at https://lifewaykefir.com/webinars-reports/
• ·Products sold in United States, Mexico, Ireland, South Africa, United Arab Emirates, and France
• ·Company recognized as TIME Growth Leader, Dairy Foods' Processor of the Year 2025, Forbes' Best Small Companies, Inc.'s 2025 Best in Business (Best Challenger Brands)

01-04-2026

Burkett Financial Services, LLC filed its 13F-HR report on April 1, 2026, disclosing total holdings of $291,821,247 across 251 positions as of March 31, 2026. The portfolio is heavily weighted toward ETFs, with top holdings including Schwab US Dividend Equity ETF at $52,860,401 (1,722,959 shares), Schwab US Large Cap Growth ETF at $47,555,568 (1,632,528 shares), and MSCI EAFA Hedged Dollar ETF at $24,425,342 (494,440 shares). No period-over-period changes are provided in the filing.

• ·Filing covers period ending 03-31-2026
• ·All positions reported as SOLE ownership with 0 SH PRN and 0 SH OTR
• ·Filer located at 128 East Main Street, Ste. 201, Rock Hill, SC 29730